
|Articles|October 24, 2012
Novel oral OAB agent now available to pharmacies
Astellas Pharma US, Inc. has announced that mirabegron (Myrbetriq), indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency, is now available through U.S. pharmacies.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
2
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
3
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
4
ACOU085 shows promise for cisplatin-induced hearing loss in patients with testicular cancer
5











